$FLGT

Gao Hanlin sold $17K of FLGT

Gao Hanlin (Chief Scientific Officer) sold 945 shares of Fulgent Genetics, Inc. (FLGT) at $17.60 on 2026-05-27.

Original reporting
SEC EDGAR · Gao Hanlin
Published May 28, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:45 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$FLGT
Neutral
medium confidence
Mentioned
$FLGT
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FLGTNeutralLow
01

Why it matters

The only new information is the insider sale details (945 shares at $17.60) and the absence of a 10b5-1 plan.

02

Market read

Traders may note insider selling, but the disclosure lacks fundamental drivers and is unlikely to move the stock materially on its own.

03

What to watch

The filing does not indicate whether other insiders sold/bought, and the transaction size is small relative to typical institutional flows.

Relevance 3/10Novelty 3/10Timing: filed 2026-05-28 after-hours/late session; reflects sale dated 2026-05-27

Background

The article is a SEC Form 4 insider transaction disclosure for Fulgent Genetics, Inc.

Company-level read

Ticker impact

$FLGTNeutralMedium confidence
Context

Fulgent Genetics insider Gao Hanlin sold 945 shares at $17.60 via an open-market sale, disclosed on Form 4.

Expected impact

Limited near-term impact; any reaction is likely sentiment-driven rather than information-driven.

Evidence & confidence

Form 4 shows an officer sale (945 shares, $16,632) with no pre-arranged 10b5-1 plan, but the filing provides no new company-specific operational or financial information.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None.

None.

Counterpoint

Insider sales can be driven by diversification, taxes, or personal liquidity needs and may not signal reduced confidence.

Key entities

  • Fulgent Genetics, Inc.

    Subject of the Form 4 insider sale by its Chief Scientific Officer.

  • Gao Hanlin

    Chief Scientific Officer who sold 945 shares in an open-market transaction.

Related articles

$FLGTMedAI 8/10

Fulgent Genetics (FLGT) Q2 2026 Earnings Call Transcript

Fulgent Genetics (FLGT) reported Q2 2026 revenue of $85.4M, up 4% year over year and 20% sequentially, driven by Bako Diagnostics and StrataDX integration. Non-GAAP gross margin was 31.3% and Adjusted EBITDA was a $17.1M loss. Full-year revenue guidance was cut to $330M-$340M due to lower collection rates from a billing system transition.

$FLGTMed

Fulgent Genetics, Inc. (FLGT): Results of Operations and Financial Condition

Fulgent Genetics, Inc. (FLGT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 flgt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Fulgent Reports Second Quarter 2026 Financial Results • Revenue of $85.4 million, growing 20.1% sequentially • GAAP gross profit of $25.7 million, or GAAP gross margin of 30.1%; Non-GAAP gross profit of $26.8 million, or Non-